Scientific Ind Stock Price, News & Analysis

Scientific Industries (OTCQB: SCND) will file its Form 10-Q and issue third quarter fiscal 2025 results for the period ended September 30, 2025.

The company will host an investor conference call on November 20, 2025 at 11:00 AM Eastern Time. Participants may dial (844) 481-2706 or (412) 317-0662 (international), or join a live webcast at https://www.scientificindustries.com/investor-relations/ or https://app.webinar.net/85AGrAdVN1d. A replay is available through November 27, 2025 at (855) 669-9658 or (412) 317-0088 (international) (access code 4098504), and for 30 days on the investor relations site.

Company contacts listed include Helena R. Santos, CEO and President, and investor relations via Lytham Partners.

Scientific Industries (OTCQB:SCND), a developer of bioprocessing products and vision-based pill counters, will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.

The presentation will be accessible through the conference website and available for replay afterward. Investors interested in one-on-one meetings can arrange them through Lytham Partners.

Scientific Industries (OTCQB:SCND), a developer of bioprocessing products and vision-based pill counters, reported Q2 2025 financial results. The company secured $10 million through the strategic divestiture of its Genie Division. Q2 revenues were $2.3 million, down 12% year-over-year, while reporting a net loss of $1.5 million.

The company's Torbal Division saw an 11% sales increase, with VIVID sales up 16% year-over-year. The VIVID system has been trained on over 7,700 pill images and is scheduled for commercial launch in Q1 2026. The company's DOTS MPS Platform demonstrated significant productivity improvements in customer studies, with optimization runs reduced from 215 to 10 while maintaining high yields.

The company ended Q2 with $1.3 million in cash and investments, prior to the Genie divestiture, and expects several key product launches in the bioprocessing segment during H2 2025.

Scientific Industries (OTCQB:SCND), a developer of bioprocessing products and vision-based pill counters, has scheduled its second quarter fiscal year 2025 financial results conference call for August 20, 2025, at 11:00 AM Eastern Time.

The company will file its Form 10Q and release financial results for the quarter ended June 30, 2025, on August 19, 2025. Investors can participate by dialing (844) 481-2706 (domestic) or (412) 317-0662 (international), or via webcast on the company's Investor Relations page. A replay will be available through August 27, 2025.

Scientific Industries (OTCQB: SCND) has completed a strategic transformation by selling its Genie Division to Troemner, LLC for $9.6 million in cash, plus potential earnout of up to $1.5 million. The company is pivoting from its 70-year legacy in vortexing technologies to focus on two AI-driven platforms: pharmacy automation through VIVID and biomanufacturing with DOTS™.

The VIVID platform, developed by the Torbal division, has deployed nearly 2,000 units for automated pill counting and is developing the industry's first ML pill library for Q1 2026. The Scientific Bioprocessing division's DOTS™ platform aims to digitize bioproduction with real-time data capabilities.

The company secured $1.5 million in additional financing through stock and warrant sales in April 2025. Combined with previous funding of $27 million since 2020 and the Genie division sale proceeds, Scientific Industries is positioned to accelerate growth in its digital platforms.

Scientific Industries (SCND) announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference, scheduled for May 29, 2025. The virtual event will feature a webcast presentation at 12:30 p.m. ET and one-on-one meetings with investors. The company, a life sciences tool provider, specializes in laboratory equipment manufacturing, including the Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the DOTS brand. Through its subsidiary Scientific Bioprocessing (SBI), the company offers bioprocess sensors, actuators, and data analytics software for bioprocessing monitoring and control.

Scientific Industries (OTCQB: SCND) reported Q1 FY2025 financial results with mixed performance. The company's Benchtop Lab Equipment Operations saw a 5% revenue increase to $2.3 million, while total net revenues decreased 3.1% to $2.4 million compared to Q1 FY2024. The company's net loss improved to $1.78 million ($(0.16) per share) from $2.05 million ($(0.20) per share) year-over-year. Notable achievements include securing $1.5 million in equity financing, receiving first peer-reviewed validation of DOTS MPS Platform, and beginning shipments of VIVID WORKSTATION. International sales declined 32.5% to $577,200, while gross margin slightly improved to 42.2%. The company's cash position stood at $1.3 million as of March 31, 2025.

Scientific Industries (OTCQB: SCND), a life sciences tool provider, will release its first quarter fiscal year 2025 financial results for the period ended March 31, 2025. The company will file Form 10Q and issue a press release after market close on May 13, 2025, followed by a conference call on May 14, 2025, at 11:00 AM Eastern Time.

Investors can participate by dialing (844) 481-2706 (domestic) or (412) 317-0662 (international). A webcast will be available on the company's Investor Relations page, with replay access through May 21, 2025. Scientific Industries specializes in laboratory equipment manufacturing, including the Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the DOTS brand.

Scientific Industries (OTCQB: SCND) has secured $1.6 million in private placement funding to advance its SBI's DOTS Platform, a real-time bioprocessing system. The offering includes 1,550,000 shares of common stock at $1.00 per share, with each share including a warrant to purchase an additional share at $1.00 within six months.

The company plans to launch its first-in-class optical pH sensor and high-performance liquid injection system in the second half of 2025. The DOTS MPS platform aims to establish a new standard in parallel bioprocessing for AI and digital biology applications, providing affordable, structured, reliable, and repeatable data for shake flask research.

Brookline Capital Markets, a division of Arcadia Securities, , served as the exclusive placement agent for the offering.